TRANDATE
LOE ApproachingNDAORALTABLET
Approved
Aug 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRANDATE is an oral tablet small-molecule antihypertensive agent approved in 1984 by the FDA. The generic name is labetalol, a combined alpha and beta-adrenergic blocker used to treat hypertension. It works by blocking both alpha and beta-adrenergic receptors, reducing peripheral vascular resistance and heart rate to lower blood pressure.
LOE Approaching
With LOE approaching, the brand is in transition; expect consolidation of commercial headcount and shift toward generic/authorized generic strategy rather than branded promotion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRANDATE offers limited career advancement opportunities due to its LOE approaching status and mature market position. Roles available are primarily in generic transition, compliance, and maintenance of existing market share rather than growth or innovation.
Generic/Brand ManagerRegulatory Affairs Specialist
Worked on TRANDATE at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.